ClinicaliQ Trial Snapshot
- DRAGON Registry – International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. — Recruiting • Oncology • NCT07717437.
- What is being tested: Combined portal and hepatic vein embolization (PVE/HVE) as a preoperative strategy to increase future liver remnant volume before surgical resection in patients with primarily unresectable liver cancer or metastases, comparing outcomes against standard portal vein embolization (PVE) alone.
- Patient eligibility overview: International cohort includes patients with primary liver malignancies or hepatic metastases deemed initially unresectable, who require preoperative liver volume augmentation through embolization techniques prior to planned surgical resection.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.
Eligibility Snapshot
- : * Patients who have undergone PVE/HVE or technical variations on this procedure * 18 Years and older * Men and women
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.